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Introduction
Bronchopulmonary dysplasia (BPD) was described as a new 
lung disease in preterm infants with respiratory distress syn-
drome (RDS) by Northway et al., in 19671. They described this 
syndrome in premature infants exposed to high supplemental 
oxygen and invasive mechanical ventilation who developed 
lung injury with specific airway histopathological features. 
BPD has evolved over the past five decades with the advent 
of new and effective perinatal strategies, including the use of 
antenatal steroids and surfactants, restricted use of oxygen, and 
a focus on the use of non-invasive, gentler modes of ventilation2. 
Despite this, BPD remains one of the most common complica-
tions associated with prematurity3. Newer BPD tends to have 
a milder initial clinical presentation of the illness compared to 
old BPD. A subgroup of infants with new BPD are ventilator-
dependent and develop severe disease as it moves from the early 
to evolving and established phases4,5. BPD continues to be a 
major cause of respiratory morbidities in the modern era as 
we push the limits of viability and see increased survival of 
extremely preterm infants born at 22–24 weeks of gestation6. In 
this review, we discuss the new advances in understanding the 
pathobiology of this disease, the current controversy regarding the 
definition of BPD, use of the novel “omic” approaches in BPD, 
and how this affects our assessment of this disease. We also dis-
cuss the current and upcoming therapies for the management 
of BPD and summarize the unanswered questions that require 
further research to improve the outcomes of premature infants 
with BPD.
Epidemiology and pathophysiology
Based on studies from various neonatal networks across 
many countries, including the United States, Canada, Korea, 
China, and India, the prevalence of BPD has been reported to 
be quite variable, ranging from 11 to 50%, and can be attrib-
uted to differences in the criteria of diagnosis and management 
approaches7. The incidence of BPD increases with a decrease in 
gestational age (GA) and birth weight6. The other perinatal fac-
tors affecting it are male sex8, intrauterine growth restriction9, 
chorioamnionitis10, smoking11, and race/ethnicity9. Postnatal fac-
tors also increase the risk for BPD and poor outcomes, includ-
ing RDS at birth, requirement for invasive mechanical ventilation 
and supplemental oxygen, lung inflammation, pulmonary vascu-
lar disease, air leaks, infections, presence of hemodynamically 
significant patent ductus arteriosus, and nutritional deficiencies12.
A potential role for placental insufficiency in the develop-
ment of BPD and BPD-associated pulmonary hypertension 
(PH) has been proposed and investigated in recent years. Pla-
centa-mediated complications in pregnancy are associated with 
moderate to severe BPD in very preterm infants. This was inde-
pendent of GA and birth weight13. Fetal growth restriction can 
predispose to impaired lung development. Similarly, decreased 
placental villous vascularity was seen in BPD-associated 
PH14,15. These studies show that placental disturbances play 
a vital role in lung alveolarization and represent a novel and 
important area in lung developmental pathobiology16,17.
The microbiome is also emerging as an important factor in dis-
ease pathobiology, and studies have revealed differences in the 
airway microbiome of preterm and term infants and infants with 
BPD. Furthermore, longitudinal changes in the airway micro-
biome of preterm infants requiring invasive mechanical ventila-
tion may be associated with severity of BPD, although it is yet 
to be determined if these changes are causal or a consequence 
of the management of these infants. Preterm infants <34 weeks 
GA and birth weight 500–1,250 g who eventually developed 
severe BPD demonstrated abundance of Ureaplasma and less 
Staphylococcus in their tracheal aspirates in the first few days 
after birth18,19. All of these studies attest to the potential contribu-
tion of the microbiome in the dysregulated development of the 
lungs20,21. Figure 1 summarizes the factors contributing to the 
pathobiology of new BPD.
Diagnosis and assessment
Does an ideal definition of bronchopulmonary dysplasia 
exist?
Various definitions exist for diagnosing BPD; however, most 
of them suffer from the primary limitation of utilizing a treat-
ment modality as the primary factor defining the disease rather 
than the disease pathology or severity22. One of the commonly 
used definitions of BPD is the NIH consensus definition by 
Jobe et al., which recommends diagnosing infants with BPD 
based on their oxygen exposure and determines severity by 
assessing their respiratory support at 36 weeks postmen-
strual age (PMA)23. A major limitation of the available defini-
tions of BPD is their inability to diagnose BPD in infants dying 
from severe respiratory failure before 36 weeks PMA. These 
infants comprise a subset of extremely preterm infants who are 
at high risk for developing severe BPD if they survive. An addi-
tional challenge comes from the increasing use of high-flow 
nasal cannula for oxygen therapy that provides a variable degree 
of positive end-expiratory pressure, thus creating the conun-
drum of whether these infants should be classified on the basis 
of supplemental oxygen concentration alone or by including the 
positive pressure that they receive. On the other end of the spec-
trum, we have infants on 100% oxygen via very low nasal can-
nula flows who may not be appropriately categorized with 
the available definitions. Another group of infants difficult to 
classify are those dependent on positive-pressure ventilation 
for airway abnormalities or abnormal respiratory control with no 
or minimal parenchymal lung disease. These infants should not 
be classified as having BPD, but we do not have the adequate 
means to re-categorize them currently24.
In the summary from the workshop on BPD organized by the 
Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), the expert panel proposed an 
updated definition of BPD25. In this new definition, the panel 
addresses the use of contemporary modes of ventilation and 
stage BPD based on the precise respiratory support and frac-
tion of inspired oxygen (FiO
2
) being used. They also exclude 
the need for supplemental O
2
 exposure for 28 days and include 
“radiographic confirmation of parenchymal disease”26. The use of 
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this definition accurately predicted death or serious respiratory 
morbidity at 18–26 months corrected age in 81% of infants in the 
study27. An ideal definition of BPD should be objective, take 
into account the pathophysiology, and be able to predict 
meaningful long-term outcomes28,29. Use of long-term biomarkers 
for assessing lung injury30, imaging studies like functional 
magnetic resonance imaging to assess lung structure31, and novel 
ways to assess pulmonary function will be required to create a 
new classification system for BPD that is more centered on lung 
function evaluation and pathophysiology28.
The “omics” in bronchopulmonary dysplasia
In order to accurately assess the lung pathology in BPD, several 
traditional biomarkers have been utilized, but, owing to variable 
phenotypes seen in BPD, these biomarkers have low predictive 
value30. In the past decade, newer technologies have allowed 
the detailed analysis of “big data sets” through bioinformatics 
to help in delineating the pathogenesis, mechanisms, and 
diagnosis of diseases. Novel systems biology-based “omic” 
approaches can be utilized to define the multiple cellular 
and humoral interactions that regulate the dysregulated lung 
development and injury response in BPD.
Metabolomics has been utilized to develop a panel of biomarkers 
to identify neonates at risk of developing BPD. Metabolomics 
consists of quantitative analysis of many low-molecular-mass 
metabolites found in a specific cell, organ, or organism involving 
substrates or products of a defined metabolic pathway. The 
changes in metabolite composition reflect the interaction 
among a genetic predisposition, a specific pathophysiological 
state, and environmental stimuli and can provide a unique 
fingerprint of those pathophysiological changes that predict the 
predisposition to the disease32. La Frano et al., studied the 
metabolomics in umbilical cord blood from 10 neonates who 
later developed BPD and compared them to 10 controls and 
found an alteration in lipid metabolism that may be responsible 
for an immaturity of lipid biosynthesis in these infants33. In 
another study evaluating tracheal aspirate fluid from 68 preterm 
neonates on the first day of life, the authors demonstrated that 
neonates who develop BPD later in life have higher levels of 
serine, alanine, taurine, and citrulline compared to neonates  who 
do not develop BPD34.
As mentioned earlier in this review, various studies have 
demonstrated associations between dysbiosis of the airway 
microbiome and BPD; however, the direction of causality 
between airway injury during lung development and respiratory 
colonization with microorganisms is unclear. A systematic review 
of six studies investigating the airway microbiome of preterm 
infants showed that early microbiome contains Firmicutes and 
Figure 1. Factors contributing to the pathobiology of new bronchopulmonary dysplasia (BPD). Premature infants at risk owing to 
maternal and infant factors develop new BPD when exposed to invasive mechanical ventilation and hyperoxia.
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Proteobacteria as the predominant phyla and Staphylococcus 
and Ureaplasma as the predominant genera19. Infants who 
eventually developed severe BPD demonstrated an abundance 
of Ureaplasma and less Staphylococcus in their tracheal 
aspirates initially after birth18. BPD progression was associated 
with increased microbial community turnover, change in relative 
abundance of Firmicutes and Proteobacteria, and decrease in 
Lactobacilli19,20. Metabolomics and microbiomics can be inte-
grated to help guide us to the pathways that are activated in 
newborns who develop BPD based on the microbiome they have 
in their airways/lungs32. Lal et al. investigated this relationship 
between airway microbiome and metabolome at birth. They 
found that in infants with BPD, there is an increase in Proteo-
bacteria, a reduction in Lactobacilli, and a decrease in the ratio 
of acetyl-CoA/propionyl-CoA carboxylase, indicating a cur-
tailed fatty acid β-oxidation pathway. These changes suggest that 
the metabolic activity of the airway microbiome may in fact 
modulate the metabolome. The authors further postulated that 
the lipid metabolites from the bacteria may cause increased 
airway inflammation, leading to BPD35.
Proteomics is the large-scale study of the structure and function 
of proteins which may help evaluate the networks of proteins 
that can specify the real-time status of disease state and 
protein function modulation36. Analysis of bronchoalveolar lavage 
fluid in preterm babies using a proteomics-based approach 
showed that calcium signaling-related proteins differed with 
BPD severity37. In a study evaluating plasma proteins using pro-
teomics in preterm infants, it was noted that there was decreased 
gelsolin, afamin, and carboxypeptidase N subunit 2 levels 
in cord blood38. In addition, there was decreased hemoglobin 
subunit gamma-1 and galectin-3 binding protein levels, along 
with increased serotransferrin in plasma at 36 weeks PMA38. 
In a recent study by Förster et al., proteomic screening was 
utilized in plasma samples from preterm infants to identify 
novel biomarkers of BPD that could help in the early identifi-
cation of such infants. They reported that increased levels of 
sialic acid-binding immunoglobulin-type lectin (SIGLEC)-14 
and basal cell adhesion molecule (BCAM) along with decreased 
levels of angiopoietin-like 3 (ANGPTL3) in the first week of 
life can predict the outcome of BPD with high specificity and 
sensitivity39.
In the field of genomics, various approaches including inte-
grated genomic analysis40 and gene expression profiling41 have 
led to the identification of novel pathways of lung development 
and repair (the cell-surface glycoprotein CD44, phosphorus 
oxygen lyase activity) and novel molecules and pathways 
(adenosine deaminase, targets of microRNA [miR]) that are 
associated with the genetic origins of BPD42. In addition to 
whole exome sequencing and whole genome sequencing to 
identify non-common variants in patients with BPD, RNA 
sequencing methods have been developed to evaluate protein- 
coding mRNA, transcripts of pseudogenes, long non-coding RNA 
(lncRNA), and miRs43. In the last few years, miRs have been 
described as important mediators of normal growth, development, 
and disease. In a recent study, Syed et al. showed that 
miR-34a levels are significantly increased in the lungs of neonatal 
mice exposed to hyperoxia; deletion or inhibition of miR-34a 
improved the pulmonary phenotype and BPD-associated pul-
monary arterial hypertension (PAH) in mouse models of BPD44. 
Pharmacologic inhibition of miR-34a can thus be used as a 
potential therapeutic option in neonates to prevent hyperoxia-
induced lung injury45. In another study, increased expression 
of miR-451 was noted in animal models of BPD and inhibi-
tion of miR-451 was shown to improve the cardiopulmonary 
phenotype46. Similarly, potential roles for miR-17∼9247, miR-29b48, 
miR-876-3p49, miR-199a-5p50, and miR-48951 have been described 
in the pathogenesis of BPD.
New and upcoming therapies in the management and 
prevention of bronchopulmonary dysplasia
Despite the high prevalence of BPD, no new drugs have been 
approved for the management of this disease over the past 
two decades. To date, among the many tried interventions, 
postnatal use of vitamin A52,53, caffeine54, and corticosteroids55 
are the only interventions that have led to a decrease in the rate 
of BPD. The use of vitamin C in pregnant smokers has been 
shown to improve pulmonary function tests in newborns at birth 
and 3 months of age with decreased wheezing up to 1 year of 
age56,57. Since smoking is a significant risk factor for BPD, use 
of vitamin C in this population may help to mitigate the effects 
of smoking on the developing lung; however, no clinical trials 
have evaluated this potential therapy as yet specifically to 
decrease BPD. Systemic corticosteroids have been used for dec-
ades to decrease BPD, with dexamethasone being one of the 
initial therapies to have been adopted. Although dexametha-
sone clearly decreased the rate of BPD, it caused various short- 
and long-term adverse effects that have led to a decrease in its 
use over time58. Dexamethasone lacks mineralocorticoid activity 
and has been associated with serious neurodevelopmental 
impairment due to apoptosis in areas of the brain critical to 
learning and memory59. Over the past few years, hydrocortisone 
use has gained popularity in extremely premature infants either 
for the management of hemodynamic failure or for the prevention 
of BPD55. An individual patient data meta-analysis including 
almost 1,000 extremely preterm infants showed that early 
low-dose hydrocortisone therapy is beneficial for survival 
without BPD and without adverse effects on neurodevelopment 
at 2 years of age60. Data from two clinical trials have shown that 
in very low-birth-weight infants with severe RDS, intra-tracheal 
administration of surfactant/budesonide combination compared 
with surfactant alone significantly decreased the incidence of 
BPD or death61,62. Larger trials are underway to determine if 
this should be recommended as standard of care. Mesenchymal 
stem cell (MSC) therapy and insulin-like growth factor (IGF)-1 
(in combination with IGF-binding protein 3 [IGFB3]) are the 
new investigational agents that are being explored currently to 
prevent BPD. Figure 2 denotes the new and emerging therapies 
for the management and prevention of BPD.
Stem cell-based therapies in bronchopulmonary dysplasia
MSCs play a vital role in lung development, and the therapeutic 
use of MSCs to treat and prevent BPD has emerged as a prom-
ising field. In preclinical studies, exogenous stem cells protect 
and repair hyperoxia-induced lung injury and improve survival. 
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The precise mechanism by which they act is not completely 
known; however, it is believed that MSCs act primarily via a 
paracrine effect63. In a systematic review evaluating the various 
cell based therapies in preclinical BPD, MSCs were found to 
be the most efficacious among all interventions, although they 
were exclusively investigated in the rodent hyperoxia-exposed 
model of BPD64. Human umbilical cord tissue and cord blood 
have been identified as a potential source of MSCs and have 
been further explored as a feasible source of these cells and 
exosomes65,66. At least two phase I clinical trials of human 
cord blood-derived MSCs have been successfully conducted 
in South Korea and the United States67,68. Another source for 
similar cells is from placental membranes, human amnion 
epithelial cells (hAECs), which have shown considerable promise 
in preclinical models of BPD. The first human clinical trial of 
hAECs in neonates with BPD has been completed to assess 
the safety of these cells69.
Insulin-like growth factor-1
IGF-1 is a significant regulator of lung angiogenesis, fetal 
growth, and development. Lower levels of IGF-1 have been 
independently associated with increased risk of BPD and retin-
opathy of prematurity. In neonatal rodent models of hyperoxia- 
induced lung injury, the administration of IGF-1 seems to 
reduce lung injury70. In a phase II clinical trial, treatment with 
recombinant human IGF along with its binding protein (rhIGF-1/
rhIGFBP-3) reduced the incidence of severe BPD as a secondary 
outcome71.
Summary
Despite great advances in lung research and evolving 
management of BPD over the years, many questions remain 
unanswered and present unique opportunities for research. The 
pathobiology of BPD is a rapidly evolving field of research with 
potential for utilizing the newer “omic” approaches to better 
understand the molecular pathways and cell interactions specific 
to injury in BPD. The development of an appropriate BPD defini-
tion that is based on pathophysiology and can predict long-term 
pulmonary outcomes remains a top priority. This would also 
help as a useful and uniform clinical end point72. As we continue 
on our search for better biomarkers in BPD, further research 
should focus on clinical, imaging, and biological markers to 
better diagnose and manage these infants. Lastly, the advancement 
in cell-based therapies provides a novel opportunity to under-
stand the biology of the repair cells and identify new targets 
in injury and repair pathways in BPD. Despite the severe lung 
injury in BPD, most infants achieve remarkable recovery of lung 
structure and function. Exploring the cause of this resilience of 
the neonatal lung will provide further insights into the pathogenesis 
of chronic lung diseases.
Figure 2. Emerging/potential therapies in the management and prevention of bronchopulmonary dysplasia. These include antenatal 
vitamin C, steroids, stem cell-based therapies, insulin-like growth factor-1 (IGF-1) in combination with IGF-binding protein-3 (IGFBP-3), and 
microRNAs.
Page 6 of 9
F1000Research 2020, 9(Faculty Rev):703 Last updated: 16 JUL 2020
References Faculty Opinions Recommended
1.  Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator 
therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J 
Med. 1967; 276(7): 357–68.  
PubMed Abstract | Publisher Full Text 
2.  Dumpa V, Bhandari V: Surfactant, steroids and non-invasive ventilation in the 
prevention of BPD. Semin Perinatol. 2018; 42(7): 444–52.  
PubMed Abstract | Publisher Full Text 
3.  Nelin LD, Bhandari V: How to decrease bronchopulmonary dysplasia in your 
neonatal intensive care unit today and “tomorrow” [version 1; peer review: 2 
approved]. F1000Res. 2017; 6(F1000 Faculty Rev): 539.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4.   Bancalari E, Jain D: Bronchopulmonary Dysplasia: 50 Years after the 
Original Description. Neonatology. 2019; 115(4): 384–91.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
5.  Bhandari A, Bhandari V: Pitfalls, Problems, and Progress in Bronchopulmonary 
Dysplasia. Pediatrics. 2009; 123(6): 1562–73.  
PubMed Abstract | Publisher Full Text 
6.  Stoll BJ, Hansen NI, Bell EF, et al.: Trends in Care Practices, Morbidity, and 
Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015; 314(10): 
1039–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7.   Thébaud B, Goss KN, Laughon M, et al.: Bronchopulmonary dysplasia. Nat 
Rev Dis Primers. 2019; 5(1): 78.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
8.  Leary S, Das P, Ponnalagu D, et al.: Genetic Strain and Sex Differences in a 
Hyperoxia-Induced Mouse Model of Varying Severity of Bronchopulmonary 
Dysplasia. Am J Pathol. 2019; 189(5): 999–1014.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9.  Bose C, van Marter LJ, Laughon M, et al.: Fetal growth restriction and chronic 
lung disease among infants born before the 28th week of gestation. Pediatrics. 
2009; 124(3): e450–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10.  Hartling L, Liang Y, Lacaze-Masmonteil T: Chorioamnionitis as a risk factor for 
bronchopulmonary dysplasia: A systematic review and meta-analysis. Arch Dis 
Child Fetal Neonatal Ed. 2012; 97(1): F8–F17.  
PubMed Abstract | Publisher Full Text 
11.  Antonucci R, Contu P, Porcella A, et al.: Intrauterine smoke exposure: A new 
risk factor for bronchopulmonary dysplasia? J Perinat Med. 2004; 32(3): 272–7. 
PubMed Abstract | Publisher Full Text 
12.  Kalikkot Thekkeveedu R, Guaman MC, Shivanna B: Bronchopulmonary 
dysplasia: A review of pathogenesis and pathophysiology. Respir Med. 2017; 
132: 170–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Torchin H, Ancel PY, Goffinet F, et al.: Placental Complications and 
Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study. Pediatrics. 2016; 
137(3): e20152163.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14.  Yallapragada SG, Mestan KK, Palac H, et al.: Placental Villous Vascularity 
is Decreased in Premature Infants with Bronchopulmonary Dysplasia-
Associated Pulmonary Hypertension. Pediatr Dev Pathol. 2016; 19(2): 101–7. 
PubMed Abstract | Publisher Full Text 
15.  Bhandari V, Lodha A: Is bronchopulmonary dysplasia decided before birth? 
Pediatr Res. 2020; 87(5): 809–10.  
PubMed Abstract | Publisher Full Text 
16.  Morrow LA, Wagner BD, Ingram DA, et al.: Antenatal Determinants of 
Bronchopulmonary Dysplasia and Late Respiratory Disease in Preterm 
Infants. Am J Respir Crit Care Med. 2017; 196(6): 364–74.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17.   Taglauer E, Abman SH, Keller RL: Recent advances in antenatal factors 
predisposing to bronchopulmonary dysplasia. Semin Perinatol. 2018; 42(7): 
413–24.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
18.  Wagner BD, Sontag MK, Harris JK, et al.: Airway Microbial Community Turnover 
Differs by BPD Severity in Ventilated Preterm Infants. PLoS One. 2017; 12(1): 
e0170120.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19.  Pammi M, Lal CV, Wagner BD, et al.: Airway Microbiome and Development of 
Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review.  
J Pediatr. 2019; 204: 126–133.e2.  
PubMed Abstract | Publisher Full Text 
20.  Lal CV, Travers C, Aghai ZH, et al.: The Airway Microbiome at Birth. Sci Rep. 
2016; 6: 31023.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21.  Surate Solaligue DE, Rodríguez-Castillo JA, Ahlbrecht K, et al.: Recent advances 
in our understanding of the mechanisms of late lung development and 
bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2017; 313(6): 
L1101–L1153.  
PubMed Abstract | Publisher Full Text 
22.  Ibrahim J, Bhandari V: The definition of bronchopulmonary dysplasia: An 
evolving dilemma. Pediatr Res. 2018; 84(5): 586–8.  
PubMed Abstract | Publisher Full Text 
23.  Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 
2001; 163(7): 1723–9.  
PubMed Abstract | Publisher Full Text 
24.  Jobe AH, Steinhorn R: Can We Define Bronchopulmonary Dysplasia? J Pediatr. 
2017; 188: 19–23.  
PubMed Abstract | Publisher Full Text 
25.   Higgins RD, Jobe AH, Koso-Thomas M, et al.: Bronchopulmonary Dysplasia: 
Executive Summary of a Workshop. J Pediatr. 2018; 197: 300–8.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
26.  Jensen EA, Wright CJ: Bronchopulmonary Dysplasia: The Ongoing Search for 
One Definition to Rule Them All. J Pediatr. 2018; 197: 8–10.  
PubMed Abstract | Publisher Full Text 
27.   Jensen EA, Dysart K, Gantz MG, et al.: The Diagnosis of Bronchopulmonary 
Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir 
Crit Care Med. 2019; 200(6): 751–9.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
28.   Bancalari E, Jain D: Bronchopulmonary Dysplasia: Can We Agree on a 
Definition? Am J Perinatol. 2018; 35(6): 537–40.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
29.  Sahni M, Mowes AK: Bronchopulmonary Dysplasia. StatPearls. Treasure Island 
(FL): StatPearls Publishing LLC.; 2019.  
PubMed Abstract 
30.  Bhandari A, Bhandari V: Biomarkers in bronchopulmonary dysplasia. Paediatr 
Respir Rev. 2013; 14(3): 173–9.  
PubMed Abstract | Publisher Full Text 
31.   Förster K, Ertl-Wagner B, Ehrhardt H, et al.: Altered relaxation times in MRI 
indicate bronchopulmonary dysplasia. Thorax. 2020; 75(2): 184–7.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
32.  Piersigilli F, Bhandari V: Metabolomics of bronchopulmonary dysplasia. Clinica 
Chimica Acta. 2020; 500: 109–14.  
PubMed Abstract | Publisher Full Text 
33.   La Frano MR, Fahrmann JF, Grapov D, et al.: Umbilical cord blood 
metabolomics reveal distinct signatures of dyslipidemia prior to 
bronchopulmonary dysplasia and pulmonary hypertension. Am J Physiol Lung 
Cell Mol Physiol. 2018; 315(5): L870–L881.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
34.  Piersigilli F, Lam TT, Vernocchi P, et al.: Identification of new biomarkers of 
bronchopulmonary dysplasia using metabolomics. Metabolomics. 2019; 15(2): 
20.  
PubMed Abstract | Publisher Full Text 
35.  Lal CV, Kandasamy J, Dolma K, et al.: Early airway microbial metagenomic 
and metabolomic signatures are associated with development of severe 
bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2018; 315(5): 
L810–L815.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36.  Piersigilli F, Bhandari V: Biomarkers in neonatology: The new “omics” of 
bronchopulmonary dysplasia. J Matern Fetal Neonatal Med. 2016; 29(11):  
1758–64.  
PubMed Abstract | Publisher Full Text 
37.  Magagnotti C, Matassa PG, Bachi A, et al.: Calcium signaling-related proteins 
are associated with broncho-pulmonary dysplasia progression. J Proteomics. 
2013; 94: 401–12.  
PubMed Abstract | Publisher Full Text 
38.   Zasada M, Suski M, Bokiniec R, et al.: Comparative two time-point 
proteome analysis of the plasma from preterm infants with and without 
bronchopulmonary dysplasia. Ital J Pediatr. 2019; 45(1): 112.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
39.   Förster K, Sass S, Ehrhardt H, et al.: Early Identification of 
Bronchopulmonary Dysplasia Using Novel Biomarkers by Proteomic 
Screening. Am J Respir Crit Care Med. 2018; 197(8): 1076–80.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
40.  Ambalavanan N, Aschner JL: Management of hypoxemic respiratory failure 
and pulmonary hypertension in preterm infants. J Perinatol. 2016; 36 Suppl 2: 
S20–S27.  
PubMed Abstract | Publisher Full Text 
41.  Pietrzyk JJ, Kwinta P, Wollen EJ, et al.: Gene expression profiling in preterm 
infants: New aspects of bronchopulmonary dysplasia development. PLoS One. 
Page 7 of 9
F1000Research 2020, 9(Faculty Rev):703 Last updated: 16 JUL 2020
2013; 8(10): e78585.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42.  Ambalavanan N, Cotten CM, Page GP, et al.: Integrated Genomic Analyses in 
Bronchopulmonary Dysplasia. J Pediatr. 2015; 166(3): 531–537.e13.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43.  Lal CV, Bhandari V, Ambalavanan N: Genomics, microbiomics, proteomics, and 
metabolomics in bronchopulmonary dysplasia. Semin Perinatol. 2018; 42(7): 
425–31.  
PubMed Abstract | Publisher Full Text 
44.  Syed M, Das P, Pawar A, et al.: Hyperoxia causes miR-34a-mediated injury via 
angiopoietin-1 in neonatal lungs. Nat Commun. 2017; 8(1): 1173.  
PubMed Abstract | Publisher Full Text | Free Full Text 
45.  Das P, Syed MA, Shah D, et al.: miR34a: A master regulator in the pathogenesis 
of bronchopulmonary dysplasia. Cell Stress. 2018; 2(2): 34–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
46.  Gilfillan M, Das P, Shah D, et al.: Inhibition of microRNA-451 is associated with 
increased expression of Macrophage Migration Inhibitory Factor and mitgation 
of the cardio-pulmonary phenotype in a murine model of Bronchopulmonary 
Dysplasia. Respir Res. 2020; 21(1): 92.  
PubMed Abstract | Publisher Full Text | Free Full Text 
47.  Robbins ME, Dakhlallah D, Marsh CB, et al.: Of mice and men: Correlations 
between microRNA-17∼92 cluster expression and promoter methylation in 
severe bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2016; 
311(5): L981–L984.  
PubMed Abstract | Publisher Full Text | Free Full Text 
48.  Durrani-Kolarik S, Pool CA, Gray A, et al.: miR-29b supplementation decreases 
expression of matrix proteins and improves alveolarization in mice exposed 
to maternal inflammation and neonatal hyperoxia. Am J Physiol Lung Cell Mol 
Physiol. 2017; 313(2): L339–L349.  
PubMed Abstract | Publisher Full Text | Free Full Text 
49.  Lal CV, Olave N, Travers C, et al.: Exosomal microRNA predicts and protects 
against severe bronchopulmonary dysplasia in extremely premature infants. 
JCI Insight. 2018; 3(5): e93994.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50.  Alam MA, Betal SGN, Aghai ZH, et al.: Hyperoxia causes miR199a-5p-mediated 
injury in the developing lung. Pediatr Res. 2019; 86(5): 579–88.  
PubMed Abstract | Publisher Full Text 
51.  Olave N, Lal CV, Halloran B, et al.: Regulation of alveolar septation by 
microRNA-489. Am J Physiol Lung Cell Mol Physiol. 2016; 310(5): L476–87. 
PubMed Abstract | Publisher Full Text | Free Full Text 
52.  Tyson JE, Wright LL, Oh W, et al.: Vitamin A Supplementation for Extremely-
Low-Birth-Weight Infants. National Institute of Child Health and Human 
Development Neonatal Research Network. N Engl J Med. 1999; 340(25): 1962–8. 
PubMed Abstract | Publisher Full Text 
53.  Londhe VA, Nolen TL, Das A, et al.: Vitamin A supplementation in extremely 
low-birth-weight infants: Subgroup analysis in small-for-gestational-age 
infants. Am J Perinatol. 2013; 30(9): 771–80.  
PubMed Abstract | Publisher Full Text | Free Full Text 
54.   Pakvasa MA, Saroha V, Patel RM: Optimizing Caffeine Use and Risk of 
Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review,  
Meta-analysis, and Application of Grading of Recommendations Assessment, 
Development, and Evaluation Methodology. Clin Perinatol. 2018; 45(2): 273–91. 
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
55.   Baud O, Watterberg KL: Prophylactic postnatal corticosteroids: Early 
hydrocortisone. Semin Fetal Neonatal Med. 2019; 24(3): 202–6.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
56.   McEvoy CT, Schilling D, Clay N, et al.: Vitamin C Supplementation for 
Pregnant Smoking Women and Pulmonary Function in Their Newborn Infants: 
A Randomized Clinical Trial. JAMA. 2014; 311(20): 2074–82.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
57.   McEvoy CT, Shorey-Kendrick LE, Milner K, et al.: Oral Vitamin C (500 mg/d) 
to Pregnant Smokers Improves Infant Airway Function at 3 Months (VCSIP). A 
Randomized Trial. Am J Respir Crit Care Med. 2019; 199(9): 1139–47.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
58.  Yoder BA, Harrison M, Clark RH: Time-Related Changes in Steroid Use and 
Bronchopulmonary Dysplasia in Preterm Infants. Pediatrics. 2009; 124(2): 
673–9.  
PubMed Abstract | Publisher Full Text 
59.  Crochemore C, Lu J, Wu Y, et al.: Direct targeting of hippocampal neurons 
for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor 
activation. Mol Psychiatry. 2005; 10(8): 790–8.  
PubMed Abstract | Publisher Full Text 
60.   Shaffer ML, Baud O, Lacaze-Masmonteil T, et al.: Effect of Prophylaxis for 
Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm 
Infants: An Individual Patient Data Meta-Analysis. J Pediatr. 2019; 207: 136–142.
e5.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
61.   Yeh TF, Lin HC, Chang CH, et al.: Early intratracheal instillation of 
budesonide using surfactant as a vehicle to prevent chronic lung disease in 
preterm infants: A pilot study. Pediatrics. 2008; 121(5): e1310–8.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
62.   Yeh TF, Chen CM, Wu SY, et al.: Intratracheal Administration of 
Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir 
Crit Care Med. 2016; 193(1): 86–95.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
63.   Strueby L, Thébaud B: Novel therapeutics for bronchopulmonary dysplasia. 
Curr Opin Pediatr. 2018; 30(3): 378–83.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
64.   Augustine S, Cheng W, Avey MT, et al.: Are all stem cells equal? Systematic 
review, evidence map and meta-analyses of preclinical stem cell-based 
therapies for bronchopulmonary dysplasia. Stem Cells Transl Med. 2019; 9(2): 
158–68.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
65.   Willis GR, Fernandez-Gonzalez A, Anastas J, et al.: Mesenchymal Stromal 
Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and 
Restore Lung Function through Macrophage Immunomodulation. Am J Respir 
Crit Care Med. 2018; 197(1): 104–16.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
66.   Chaubey S, Thueson S, Ponnalagu D, et al.: Early gestational mesenchymal 
stem cell secretome attenuates experimental bronchopulmonary dysplasia in 
part via exosome-associated factor TSG-6. Stem Cell Res Ther. 2018; 9(1):  
173.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
67.  Chang YS, Ahn SY, Yoo HS, et al.: Mesenchymal stem cells for  : Phase 1 dose-
escalation clinical trial. J Pediatr. 2014; 164(5): 966–972.e6.  
PubMed Abstract | Publisher Full Text 
68.   Powell SB, Silvestri JM: Safety of Intratracheal Administration of Human 
Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low 
Birth Weight Preterm Infants. J Pediatr. 2019; 210: 209–213.e2.  
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation 
69.   Lim R, Malhotra A, Tan J, et al.: First-In-Human Administration of Allogeneic 
Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia: A 
Safety Study. Stem Cells Transl Med. 2018; 7(9): 628–35.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
70.  Mandell EW, Kratimenos P, Abman SH, et al.: Drugs for the Prevention and 
Treatment of Bronchopulmonary Dysplasia. Clin Perinatol. 2019; 46(2): 291–310. 
PubMed Abstract | Publisher Full Text 
71.   Ley D, Hallberg B, Hansen-Pupp I, et al.: rhIGF-1/rhIGFBP-3 in Preterm 
Infants: A Phase 2 Randomized Controlled Trial. J Pediatr. 2019; 206: 56–65.e8.  
PubMed Abstract | Publisher Full Text | Free Full Text |  
Faculty Opinions Recommendation 
72.  Steinhorn R, Davis JM, Göpel W, et al.: Chronic Pulmonary Insufficiency of 
Prematurity: Developing Optimal Endpoints for Drug Development. J Pediatr. 
2017; 191: 15–21.e1.  
PubMed Abstract | Publisher Full Text
Page 8 of 9
F1000Research 2020, 9(Faculty Rev):703 Last updated: 16 JUL 2020
 
Open Peer Review
  Current Peer Review Status:





















Page 9 of 9
F1000Research 2020, 9(Faculty Rev):703 Last updated: 16 JUL 2020
